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Abstract
Background: Use of complementary and alternative medicine (CAM) by women with breast
cancer is often said to be increasing, yet few data exist to confirm this commonly held belief.
The purpose of this paper is to compare overall patterns of CAM use, as well as use of specific
products and therapies at two different points in time (1998 vs 2005) by women diagnosed with
breast cancer.
Methods: Surveys were mailed to women randomly selected from the Ontario Cancer Registry
(Canada) in the spring of 1998 (n = 557) and again in the spring of 2005(n = 877).
Results: The response rates were 76.3% in 1998 and 63% in 2005. In 1998, 66.7% of women
reported using either a CAM product/therapy or seeing a CAM therapist at some time in their lives
as compared with 81.9% in 2005 (p = 0.0002). Increases were seen in both use of CAM products/
therapies (62% in 1998 vs. 70.6% in 2005) and visits to CAM practitioners (39.4% of respondents
in 1998 vs 57.4% of respondents in 2005). Women in 2005 reported that 41% used CAM for
treating their breast cancer. The most commonly used products and practitioners for treating
breast cancer as reported in 2005 were green tea, vitamin E, flaxseed, vitamin C, massage therapists
and dietitians/nutritionists.
Conclusion: CAM use (both self-medication with products and visits to CAM practitioners)
increased significantly from 1998 to 2005. Now that more than 80% of all women with breast
cancer report using CAM (41% in a specific attempt to management their breast cancer), CAM use
can no longer be regarded as an "alternative" or unusual approach to managing breast cancer.
Background
The importance of breast cancer in women, as a public
health problem, is well recognized worldwide [1,2]. In
Canadian women, breast cancer is a common malignant
neoplasm, with a lifetime risk calculated as 1 in 9 [3]. Due
to mammographic screening, early detection of disease,
and improved therapies, the rate of BC mortality is stead-
ily declining in Canada [3]. Nonetheless, in 2005, it is
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estimated that 21,600 women were diagnosed and 5,300
women died from this disease [3]. Ontario has the highest
incidence of BC cases in Canada, with 8,200 of the 21,600
new cases in 2005 [3].
There have been many surveys of CAM use among
patients with breast cancer in the US, Britain, and Canada.
Survey results among breast cancer patients find that prev-
alence of CAM use ranges from 16.5 percent to 84 percent
[4-9]. Our own study of a random sample of breast cancer
survivors in Ontario, Canada found that 66.7 percent had
used some form of CAM [8]. Women cite numerous rea-
sons for taking alternative treatments including to reduce
physical distress, fatigue, anxiety, depression, sleep distur-
bance, nausea, weight change, hair loss, diminished con-
centration, and pain.
Many reports suggest that the prevalence of CAM in cancer
patients and survivors has been increasing, yet few follow-
up studies are available to confirm this. In addition, the
use of different definitions of CAM, and thus different
instruments to measure CAM prevalence, makes it diffi-
cult to compare studies completed at different points-in-
time. The primary purpose of this paper is to compare
overall patterns of prevalence of CAM use, as well as use
of specific CAM products and therapies in two random
samples of women diagnosed with breast cancer in 1998
and seven years later in 2005, using the same survey ques-
tions and definition of CAM. Specifically, CAM was
defined as medical interventions that are not taught
widely in medical schools or generally available in hospi-
tals[10] In addition, the clinical, sociodemographic, and
characteristics of CAM consumers in 1998 are compared
with those of consumers in 2005.
Methods
At both time points (1998 and 2005), a random sample
of women 18 years and older and diagnosed with breast
cancer were selected from the Ontario Cancer Registry
based on pathology reports (See Figure 1). A mailed
reminder letter was posted approximately one week fol-
lowing the initial mail out. In addition, approximately
three weeks after the initial mailing, a final reminder letter
and second survey was mailed to each non-respondent.
This Registry is a computerized database that contains
information on virtually all Ontario residents diagnosed
with cancer. As stipulated by the Registry, permission to
contact each woman was requested from her family phy-
sician or oncologist. Up to three telephone reminders
were provided in attempts to obtain responses from as
many physicians as possible. Surveys were mailed to all
women for whom permission and mailing addresses were
received. Women who did not respond to two follow-up
letters were identified as non-responders. See Figure 1 for
details on the derivation of the sample.
The questionnaire asks women to identify which CAM
practitioners and CAM therapies/products (from a specific
list) they had ever visited or used. In 2005, each respond-
ent was also asked to indicate if she visited the practition-
ers and/or used the therapies for her breast cancer or for
some other reason. In both years, demographic informa-
tion and details about each participant's cancer (e.g.,
stage, conventional treatment, hormone receptor status)
were also collected.
Statistical analysis
Respondents of the 2005 survey were categorized as CAM
consumers or nonconsumers. CAM consumers were fur-
ther categorized as either using or not using particular
CAM products or visiting CAM practitioners. We calcu-
lated frequencies, counts, and means to describe the pat-
tern of clinical, sociodemographic and prevalence of CAM
practitioners and products characteristics for respondents
of the 2005 survey. To compare the relationship of
respondents of the 2005 group who were CAM consumers
to nonconsumers on sociodemographic and clinical char-
acteristics we calculated Fisher Exact tests for categorical
variables and independent t-tests for continuous varia-
bles. We calculated Z-values for independent proportions
(two-sided) to compare sociodemographic and clinical
characteristics as well as the prevalence of CAM products
used and practitioners visited between the 1998 and the
2005 respondents. The data were analyzed using Statisti-
cal Package for Social Sciences for Windows, version 12.0
(SPSS, Chicago, ILL).
This study was approved by the University of Toronto Eth-
ics Review Office and the Institutional Review Board for
Human Subject Research at the University of Michigan
Medical School.
Results
In 1998, the survey was mailed to 557 women and the
final response rate was 76.3 percent (411/539). Seven of
the 1998 respondents were reported to have died and 11
women reported that their first diagnosis of cancer was
prior to 1994 and thus did not meet the inclusion criteria
for the study. Thus these women were not counted in the
denominator when calculating the response rate for the
study. See Boon et al. 2000 for additional details on the
1998 data collection [8]. In 2005, the survey was mailed
to 877 women who were diagnosed with breast cancer
between 2001 and 2003. A total of 541 surveys were
returned and sixteen families provided information that
the potential participant had died. In addition, 31 surveys
were removed from the analysis because the individual
reported her date of diagnosis as being prior to 2001. Thus
the final response rate in 2005 was 63 percent (541/(877-
16)). See Zick et al. 2006 for additional details on the
2005 data collection[11]BMC Women's Health 2007, 7:4 http://www.biomedcentral.com/1472-6874/7/4
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Participants
Table 1 provides demographic and breast cancer diagno-
sis/treatment data. The 2005 group was surveyed signifi-
cantly closer to their date of diagnosis compared to the
1998 group and had a slightly higher level of education.
Compared to the 1998 cohort, significantly fewer
respondents in 2005 reported having surgery, but signifi-
cantly more reported having chemotherapy and hormone
therapy for their breast cancer.
Use of CAM
In 2005, 81.9 percent of women reported using either a
CAM product/practice or seeing a CAM therapist at some
time in their lives as compared with 66.7 percent in 1998
(p = 0.0002). Increases were seen in both use of at least
one CAM product or therapy (70.6 percent in 2005 vs. 62
percent in 1998) and visits to CAM practitioners (57.4
percent of respondents in 2005 versus 39.4 percent or
respondents in 1998). In both years, the median number
of CAM practitioners ever seen was one and the median
number of products/practices ever used was two. Women
in 2005 reported that 41 percent (n = 220) used CAM as
part of the management of their breast cancer. The most
commonly used products and practitioners for managing
breast cancer included green tea, vitamin E, flaxseed and
vitamin C, massage therapists and dietitians/nutritionists
(see Table 2). Questions about the use of CAM specifically
to manage breast cancer were not asked in the 1998 sur-
vey.
Table 3 provides details on use of specific CAM practition-
ers and products in 1998 compared to in 2005. Significant
increases were seen in use of body work practitioners
(including Reiki practitioners, massage therapists, thera-
peutic touch practitioners and shiatsu practitioners), acu-
puncturists/traditional Chinese medicine (TCM)
practitioners, homeopathic practitioners and a general
"other" category in 2005 compared to 1998. Significant
increases were also seen in use of herbal remedies overall
and specifically in the use of green tea and special foods/
diets. Use of Essiac (Essiac is a blend of at least four herbs
(burdock root (Arctium lappa), Indian rhubarb (Rheum
Derivation of the sample Figure 1
Derivation of the sample.
No MD Response: 
1998=350; 2005=1088 
Response from MD: 
1998=871; 2005=1088 
Ontario Cancer Registry: 
1998 = 1221; 2005=2541 
Permission 
Denied: 
1998=127 
2005=224 
Deceased: 
1998=64 
2005=73 
MD Not 
Seeing Patient: 
1998=84; 
2005=204 
Permission 
Received: 
1998= 596 
2005=952 
Address Unknown: 
1998=39 
2005=75 
Surveys Sent: 
1998=557 
2005=877 BMC Women's Health 2007, 7:4 http://www.biomedcentral.com/1472-6874/7/4
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palmatum), sheep sorrel (Rumex acetosella) and the inner
bark of slippery elm (Ulmus fulva or U. rubra) significantly
decreased.
Discussion
Overall, we found that both the use of CAM products and
visits to CAM practitioners by women diagnosed with
Table 1: Patient characteristics
Characteristics 1998
N = 411
n (%) or Mean (SD)
2005
N = 527
n (%) or Mean (SD)
P-value*
Mean age (years) 57.9 (11.3) 60.9 (13.3) <0.01(1)
Months since first diagnosis with BC†§ 34.9 (8.75) 27.5 (5.4) <0.01(1)
Had surgery for their BC 394 (95.8) 479 (90.8) <0.01(2)
Had radiotherapy for their BC 263 (64.1) 350 (66.5) 0.44(2)
Had chemotherapy for their BC 152 (37.1) 234 (44.4) 0.02(2)
Had hormone therapy for their BC 114 (27.8) 273 (51.8) <0.01(2)
Married 294 (71.6) 335 (63.5) 0.01(2)
North American/European cultural group 337 (82.0) 405 (76.8) <0.01(2)
Completed more than high school 202 (49.2) 295 (56.0) 0.03(2)
Household annual income > $40,000§ 204 (49.7) 245 (46.4) 0.54(2)
* (1) Based on an independent sample t-test, (2) based on a two-sided Z-score
† Calculated as the number of months between a woman's date of diagnosis to April 1st 1998 for the 1998 cohort and to September 1st 2005 for the 
2005 cohort
± BC= Breast cancer
§Income based on Canadian dollars for total household income (not specified if before or after taxes) and total household income in Canadian 
dollars before taxes in 2005 cohort
Table 2: CAM Products and Practitioners most commonly used by 2005 cohort for symptoms associated with their breast cancer
Product n (%)
Green Tea 71 (13.3)
Vitamin E 70 (13.2)
Flax Seeds 66 (12.4)
Vitamin C 65 (12.3)
Special Food/Diets 53 (10.0)
Meditation 39 (7.4)
Fish Oil 35 (6.6)
Beta-carotene 32 (6.0)
Essiac 29 (5.5)
Other* 28 (5.3)
Soy 27 (5.1)
Practitioner n (%)
Massage Therapist 51 (9.8)
Dietitian/Nutritionist 45 (8.5)
Reiki Practitioner 26 (4.9)
Naturopath 25 (4.7)
Other* 24 (4.5)
Homeopath 23 (4.3)
Therapeutic Touch Practitioner 19 (3.6)
Herbalist 14 (2.6)
Reflexologist 12 (2.3)
TCM Practitioner† 12 (2.2)
Chiropractor 11 (2.1)
* Other products include yoga, chelation therapy, music/art therapy, noni juice/rain tree products, visualization, relaxation therapy, aboriginal 
medicine, exercise, flower essence, progesterone and other practitioners include aboriginal sweat & healing, brain respiration, cancer consultant, 
doctor of biomolecular medicine, exercise, iridologist, lymph clinic, muscle therapy, music and art therapy, occupational/physiotherapist, osteopath,
† TCM = Traditional Chinese MedicineBMC Women's Health 2007, 7:4 http://www.biomedcentral.com/1472-6874/7/4
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breast cancer significantly increased from 1998 to 2005.
In 2005, 81.9 percent of respondents reported using CAM
(41 percent to help manage their breast cancer) compared
to 66.7 percent in 1998, suggesting that in 2005 CAM use
has become the "norm" in this patient population.
The observed increase in CAM use appears not to be
explained by changing demographics in the breast cancer
population. The two cohorts were approximately the
same with respect to age and income levels. The differ-
ences in ethnicity, the percentage that were married, and
the level of education appear not to be big enough to
account for the increases in use. For example, a mean age
difference of 3 years is unlikely to be clinically significant.
The 2005 cohort reported less surgery, but more chemo-
therapy and more hormone therapy (e.g., tamoxifen)
which may be a reflection of differences in stage of cancer
at diagnoses; however since cancer stage information was
not collected in 1998, it is not possible to assess this. The
differences in conventional treatments may also be related
to changes in therapeutic protocols for breast cancer that
have occurred since 1998.
Overall, the biggest increases were seen in the percentage
of women seeing bodywork practitioners (including mas-
sage therapists, but not chiropractors), TCM practitioners/
Table 3: Use of CAM: 1998 versus 2005
Respondents Reporting CAM
Use
n (%)
P-value*
Visits to Practitioners 1998
N = 411
2005
N = 527
Chiropractor 120 (29.2) 180 (34.2) 0.11
Body work practitioners† 94 (22.9) 228 (43.3) >0.01
Acupuncturist/TCM practitioner± 28 (6.8) 69 (13.0) >0.01
Herbalist 28 (6.8) 25 (4.7) 0.17
Naturopathic practitioner 24 (5.8) 40 (7.6) 0.29
Reflexologist 24 (5.8) 46 (8.7) 0.09
Homeopathic practitioner 17 (4.1) 41 (7.7) 0.02
Physician offering CAM therapies± 17 (4.1) N/A N/A
Spiritual/faith healer 16 (3.9) N/A N/A
Other visits(1)§7  ( 1 . 7 ) 3 6  ( 6 . 8 ) > 0 . 0 1
Colon irrigation 4 (1.0) N/A N/A
Ayurvedic practitioner N/A 4 (0.8) N/A
Craniosacral therapist N/A 10 (1.9) N/A
Dietician/Nutritionist N/A 104 (19.7) N/A
Use of Products 1998
N = 411
2005
N = 527
Vitamins/Minerals(1) # 204 (49.6) 269 (51.0)‡ 0.67
Herbal Remedies(2) # 101 (24.6) 194 (36.8)* >0.01
Green tea 71 (17.3) 145 (27.5) >0.01
Special foods/diet 63 (15.3) 140 (26.6) >0.01
Essiac 61 (14.8) 39 (7.4) >0.01
Meditation 42 (10.2) 60 (11.4) 0.57
Shark cartilage 22 (5.4) 16 (3.0) 0.07
Other therapies(2) § 22 (5.4) 39 (7.4) 0.21
Homeopathy 16 (3.9) 34 (6.4) 0.08
Faith healing 14 (3.4) N/A N/A
TCM remedy 7 (1.7) 18 (3.4) 0.11
Natural Supplements(3) # N/A 198 (37.6)† N/A
Soy N/A 58 (11.0) N/A
* Z-value for two independent proportions (two-sided) looking at change in product or practitioner use through time
†Body Work includes: reiki practitioner, massage therapist, therapeutic touch therapist, shiatsu practitioner, and pranic healer
± TCM = Traditional Chinese Medicine, CAM = complementary and alternative medicine
§(1)Others visits include: aboriginal sweat & healing, brain respiration, cancer consultant, doctor of biomolecular medicine, exercise, iridologist, 
lymph clinic, muscle therapy, music and art therapy, occupational/physiotherapist, osteopath, (2) Glucosamine/chondrotin, yoga, chelation therapy, 
music/art therapy, noni juice/rain tree products, visualization, relaxation therapy, aboriginal medicine, exercise, flower essence, progesterone
# (1) Vitamins/minerals (other than a multi-vitamin) include beta carotene and vitamins C and E; (2) Herbal remedies include garlic, ginger, and 
Hoxsey formula (or tea), Essiac, aloe, ginseng, green tea/extract : and (3) Natural supplements include acidophilus (or probiotics), CoQ10, fish oil, 
flax seed, immune support (e.g. MGN3 or Coriolus) and melatoninBMC Women's Health 2007, 7:4 http://www.biomedcentral.com/1472-6874/7/4
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acupuncturists, homeopaths and "others". This may be
related to the fact that massage therapy and acupuncture
are two of the CAM practices which are generally the most
accepted by the medical profession [12-15]. For example,
many physicians use acupuncture in their practices [16].
In addition, given that neither acupuncture nor massage
involves taking anything orally, it is likely they are per-
ceived to have fewer potential adverse effects or interac-
tions with conventional cancer treatments than some
other CAM therapies. So it is possible that conventional
MDs are either recommending these options more often
to patients or at least not discouraging patients from using
them.
Perception of safety and perceived lack of drug interac-
tions may also explain the increased use of homeopathy.
In addition, the homeopathic community was under
review by the Health Professions Regulation Advisory
Council for consideration as a future regulated health pro-
fession in Ontario during 2005 when this survey was con-
ducted [17]. Although the council hearing did not receive
much media attention at the time, it may partially explain
the increased use of homeopathy reported here.
Overall, there was a significant increase in the use of
herbal products such as garlic, ginger, ginseng and green
tea and special foods/diets. Both green tea and special
diets/foods are used by more than 10 percent of all
women diagnosed with breast cancer specifically to help
manage their breast cancer. A review of the evidence sug-
gests that there may be an overall decreased risk of cancer
associated with taking Asian ginseng (Panax ginseng), gar-
lic, green tea, soy, and tomatoes but research is extremely
preliminary and in some cases contradictory. Also, the
minimum dose associated with decreased cancer risk has
not been clearly defined for any of the supplements or
herbs [18,19]. Although there is evidence that ginger may
be useful in the management of chemotherapy-induced
nausea, it is not clear exactly what dose or dosing schedule
is best. It is also not clear what additional benefits ginger
products have over and above conventional anti-nausea
medications (fewer adverse effects are claimed) [18,19].
There are currently no herbs with significant evidence of
efficacy as cancer treatments [18,19].
Our results also found the use of Essiac significantly
decreased. Essiac has been used in Canada for over 70
years [20]. In contrast to green tea and soy, which has
received considerable media and scientific attention as
possible cancer prevention agents, Essiac has received lit-
tle notice and has no peer-reviewed clinical trials or
encouraging animal studies demonstrating any significant
beneficial effects. For example, our retrospective survey
found that Essiac did not have a significant effect on either
health related quality of life or mood states in women
with breast cancer. Women in the study were taking low
doses (total daily dose 43.6 ± 30.8 mL) of Essiac that cor-
responded to label directions found on most Essiac prod-
ucts, but appear unlikely to have significant
pharmacological effects[11] Thus, it appears at least in
part, that women are using more natural health products
that are receiving increased positive attention in the media
and by the scientific community and decreasing those that
have garnered little evidence or interest.
Several limitations of our study need to be addressed. As
with any retrospective study recall bias is a possible limi-
tation. In 1998, respondents were only asked if they had
ever used CAM products or visited CAM therapies. Thus,
although we can comment on what women in 2005 were
using to help manage their breast cancer, it is not possible
to compare this to women in 1998.
Both in 1998, and in 2005, the most up-to-date records
from the Ontario Cancer Registry were used to select sam-
ples as close to diagnosis as possible. However, given the
recent computerization of the Registry, the 2005 cohort
was surveyed almost 12 months closer to their diagnosis
of cancer than the 1998 cohort and thus may have been
more active in using CAM products and therapies to man-
age the lingering side effects of conventional cancer treat-
ments. It might also have been easier for these women to
recall the CAM they had used in the more active symptom
phase of the management of the cancer than the women
surveyed in 1998. It is possible that the difference in time
since diagnosis accounts for the changes in CAM use
reported by the two cohorts.
We originally selected a random sample from the Ontario
Cancer Registry; however we were only able to mail sur-
veys to approximately one-half of the sample from 1998
and just over one-third of the sample in 2005 (see Figure
1). Physicians declined to provide permission for women
that were too ill or emotionally unstable to respond or
were unable to speak English (less than ten percent of the
original sample). The reason we were unable to contact
most of the other women was our inability to obtain a
response from the physicians we contacted to obtain per-
mission to mail a survey to the patient. It is possible that
physicians who did not respond had more negative atti-
tudes toward CAM and may have influenced their patients
not to take CAM than those who agreed to allow their
patients to participate. Thus, our prevalence rates may be
an over-estimate of the actual prevalence of CAM use in
the population of women with breast cancer.
Conclusion
Our findings suggest that the majority of women with
breast cancer use CAM in combination with conventional
medical breast cancer treatments and this highlights theBMC Women's Health 2007, 7:4 http://www.biomedcentral.com/1472-6874/7/4
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importance of additional research on the safety, efficacy
and interactions of these products and therapies. It is
important for clinicians to routinely ask patients about
their CAM use, but making recommendations about use,
especially in conjunction with chemotherapy, radiation
therapy and hormone therapy remains problematic due
to lack of research of the potential benefits or harmful
effects of these combinations.
CAM use (both self-medication with products and visits
to CAM practitioners) increased from 1998 to 2005 in our
samples. Now that more than 80 percent of all women
with breast cancer report using CAM (41 percent in a spe-
cific attempt to management their breast cancer), CAM
use can no longer be regarded as an "alternative" or unu-
sual approach to managing breast cancer. The increasing
popularity of CAM increases the urgency for research into
the safety and efficacy of these products and therapies.
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